JP2024506384A - ロフルミラストの眼科的送達方法 - Google Patents

ロフルミラストの眼科的送達方法 Download PDF

Info

Publication number
JP2024506384A
JP2024506384A JP2023548873A JP2023548873A JP2024506384A JP 2024506384 A JP2024506384 A JP 2024506384A JP 2023548873 A JP2023548873 A JP 2023548873A JP 2023548873 A JP2023548873 A JP 2023548873A JP 2024506384 A JP2024506384 A JP 2024506384A
Authority
JP
Japan
Prior art keywords
roflumilast
administration
cornea
patient
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506384A5 (https=
Inventor
チョウドリ，バスカー
グカスヤン，ホヴハンネス・ジョン
Original Assignee
イオリクス セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イオリクス セラピューティクス，インコーポレーテッド filed Critical イオリクス セラピューティクス，インコーポレーテッド
Publication of JP2024506384A publication Critical patent/JP2024506384A/ja
Publication of JP2024506384A5 publication Critical patent/JP2024506384A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023548873A 2021-02-10 2022-02-10 ロフルミラストの眼科的送達方法 Pending JP2024506384A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163148008P 2021-02-10 2021-02-10
US63/148,008 2021-02-10
US202163261404P 2021-09-20 2021-09-20
US63/261,404 2021-09-20
PCT/US2022/015942 WO2022173923A1 (en) 2021-02-10 2022-02-10 Methods for ophthalmic delivery of roflumilast

Publications (2)

Publication Number Publication Date
JP2024506384A true JP2024506384A (ja) 2024-02-13
JP2024506384A5 JP2024506384A5 (https=) 2025-02-19

Family

ID=82704332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548873A Pending JP2024506384A (ja) 2021-02-10 2022-02-10 ロフルミラストの眼科的送達方法

Country Status (8)

Country Link
US (2) US12102622B2 (https=)
EP (1) EP4291162A4 (https=)
JP (1) JP2024506384A (https=)
AU (1) AU2022218993A1 (https=)
CA (1) CA3206106A1 (https=)
IL (1) IL304924A (https=)
MX (1) MX2023009352A (https=)
WO (1) WO2022173923A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
AU2023341161A1 (en) * 2022-09-16 2025-04-03 Iolyx Therapeutics, Inc. High concentration pharmaceutical compositions of roflumilast for ophthalmic delivery
WO2025024684A1 (en) * 2023-07-25 2025-01-30 Iolyx Therapeutics, Inc. Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529928A (ja) * 2002-05-28 2005-10-06 アルタナ　ファルマ　アクチエンゲゼルシャフト 眼の病気を治療するためのロフルミラストの眼科的使用
JP2007016024A (ja) * 2005-06-09 2007-01-25 Santen Pharmaceut Co Ltd ロフルミラスト点眼液

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59410119D1 (de) 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20040242597A1 (en) 2001-09-19 2004-12-02 Thomas Klein Combination
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
DK1906916T3 (da) * 2005-05-10 2009-01-19 Alcon Inc Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
BRPI0609227A2 (pt) 2005-05-10 2010-03-09 Alcon Inc composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos
EP1889620A4 (en) * 2005-06-09 2008-12-10 Santen Pharmaceutical Co Ltd EYE DROPS CONTAINING ROFLUMILAST
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
CA2712017C (en) 2008-01-18 2016-08-09 Oxagen Limited Compounds having crth2 antagonist activity
RS54413B1 (sr) 2008-08-22 2016-04-28 Sanofi [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita
EP2506878A2 (en) 2009-12-03 2012-10-10 Lupin Limited Process for preparing pharmaceutical ophthalmic compositions
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2014072937A1 (en) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
MX2021003633A (es) 2018-10-16 2021-05-27 Res Triangle Inst Dispositivo de depósito biodegradable subcutáneo.
EP4061332A4 (en) 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529928A (ja) * 2002-05-28 2005-10-06 アルタナ　ファルマ　アクチエンゲゼルシャフト 眼の病気を治療するためのロフルミラストの眼科的使用
JP2007016024A (ja) * 2005-06-09 2007-01-25 Santen Pharmaceut Co Ltd ロフルミラスト点眼液

Also Published As

Publication number Publication date
MX2023009352A (es) 2023-08-16
IL304924A (en) 2023-10-01
WO2022173923A1 (en) 2022-08-18
US20250009724A1 (en) 2025-01-09
AU2022218993A1 (en) 2023-08-03
US20220249451A1 (en) 2022-08-11
CA3206106A1 (en) 2022-08-18
US12102622B2 (en) 2024-10-01
EP4291162A1 (en) 2023-12-20
EP4291162A4 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
US20220184057A1 (en) Combination treatment of ocular inflammatory disorders and diseases
US20250009724A1 (en) Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) Methods of treating ocular inflammatory diseases
EA034839B1 (ru) Офтальмологический раствор
US20250255809A1 (en) Ophthalmic pharmaceutical compositions of roflumilast
CN118403054A (zh) 用于控制和/或降低近视发展的药物组合物
US20160051526A1 (en) The Local Treatment of Inflammatory Ophthalmic Disorders
JP6522592B2 (ja) １ｈ−インドール−１−カルボキサミド誘導体を含有する局所水性眼科用組成物および眼疾患の治療へのその使用
JP2009519962A (ja) 眼投与用局所メカミルアミン製剤およびその使用
HK40101566A (zh) 眼部递送罗氟司特的方法
US20250032468A1 (en) Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases
US20260083712A1 (en) Methods for treating patients with ocular comorbidities of an autoimmune disorder
US20250339419A1 (en) Methods of treating ocular inflammatory diseases
HK40113755A (zh) 治疗眼部炎性疾病的方法
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
US20160095861A1 (en) Ophthalmic ointments comprising valganciclovir hydrochloride for treating infective eye diseases
CA3014071A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
US20140213605A1 (en) Methods for treating eye disorders using opioid receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260226